PACB Stock Recent News
PACB LATEST HEADLINES
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights
Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination. The new service is a laboratory developed test that identifies sequences of DNA that repeat many times across a long stretch of the genome.
Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations
New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing
MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time.
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.